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Background & Aims: European and American guidelines have endorsed the 
Barcelona Clinic Liver Cancer (BCLC) staging system.  The aim of this study 
was to assess the performance of the recently developed Hong Kong Liver 
Cancer (HKLC) classification as a staging system for hepatocellular 
carcinoma (HCC) in Europe. 
Methods: We used a pooled set of 1693 HCC patients combining three 
prospective European cohorts. Discrimination ability between the nine 
substages and five stages of the HKLC classification system was assessed. 
To evaluate the predictive power of the HKLC and BCLC staging systems on 
overall survival, Nagelkerke pseudo R2, Bayesian Information Criterion and 
Harrell’s concordance index were calculated. The number of patients who 
would benefit from a curative therapy was assessed for both staging system.  
Results: The HKLC classification in nine substages shows suboptimal 
discrimination between the staging groups.  The classification in five stages 
shows better discrimination between groups. However, the BCLC 
classification performs better than the HKLC classification in the ability to 
predict OS. The HKLC treatment algorithm tags significantly more patients to 
curative therapy than the BCLC. 
Conclusions: The BCLC staging system performs better for European 
patients than the HKLC staging system in predicting OS. Twice more patients 
are eligible for a curative therapy with the HKLC algorithm, whether this 
translates in survival benefit remains to be investigated.  
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Key points 
• Three European cohorts from three different countries have been 
pooled to assess the Hong-Kong Liver Cancer (HKLC) staging system 
• While the HKLC 9-stages classification shows suboptimal stage 
differentiation, the HKLC 5-stages classification shows good 
discrimination between groups 
• The Barcelona Clinic Liver Cancer (BCLC) staging system performs 
better than the HKLC classification to predict the overall survival 
• The HKLC treatment algorithm tags significantly more patients to 
curative therapies than the BCLC 
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INTRODUCTION  
With a worldwide incidence of 782,000 new cases, hepatocellular carcinoma 
(HCC) is the fifth most common cancer type in men and the ninth in women, 
and the second most common cause of cancer-related death.[1] Most 
common causes for developing HCC are chronic infection with hepatitis B 
virus (HBV), hepatitis C virus (HCV), alcoholic steatohepatitis (ASH) and 
nonalcoholic steatohepatitis (NASH).  HCC presents a geographical pattern, 
with more than 85% of all worldwide cases in East Asia, sub-Saharan Africa 
and Melanesia.  In these regions, HBV prevalence is high and is therefore the 
most common cause for HCC.  In Western countries (Europe and the United 
States), HCV infections, ASH and NASH play an important role in the 
development of HCC.[1] 
The classical staging system based on TNM is not used for HCC. The TNM 
classification does not consider information regarding the liver function or the 
health status of the patient.  Several HCC-specific staging systems have been 
developed.[2], [3], [4], [5], [6], [7], [8].  The Barcelona Clinic Liver Cancer 
(BCLC) staging system is the most accepted and has been endorsed by the 
European Association for the Study of the Liver (EASL) and the American 
Association for the Study of the Liver Diseases (AASLD).  It presents the 
appealing feature of linking specific stages with treatment options. Originally 
developed for cirrhotic patients[4], the authors of this staging system 
suggested lately that the treatment of HCC in a non-cirrhotic liver should 
follow the same principles, although the efficacy and impact on outcome are 
less predictable.[9] Nevertheless, the BCLC system has been developed in 
Europe, and may be less adapted for regions where HBV is the predominant 
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etiology for HCC.  However, it has been argued that the BCLC treatment 
algorithm might be too conservative.  Some studies showed a better overall 
survival (OS) for patients who received surgical resection against those who 
received trans-arterial chemoembolisation (TACE) for intermediate HCC.[10], 
[11]  In fact, the BCLC B stage (intermediate HCC) assembles a 
heterogeneous group of patients.  Consequently, a substaging of BCLC B has 
been proposed [12], with alternative therapies such as 
radioembolisation[13],[14] or sorafenib[15] suggested for selected patients in 
this stage.  
Recently, the Hong Kong Liver Cancer (HKLC) reported a new staging 
system, which, like the BCLC, links HCC stages to treatment options.[16] 
Based on a large cohort of patients treated in the same centre and essentially 
with chronic hepatitis B as their underlying liver disease, this classification 
showed interesting features.  It was reported to be a better predictor of 
survival than the BCLC system in the cohort studied.  Furthermore, patients 
staged BCLC B and HKLC II had a survival probability of 52% at 5 years if 
they underwent surgical resection as first treatment, compared with a survival 
probability of 18.7% at 5 years if they received first-line TACE.  This algorithm 
expands the scope of surgical resection.   
Assessment of the HKLC staging system outside of Asia is essential.  In this 
study, we applied the HKLC staging system to pooled data from three 
European prospective cohorts of patients with HCC.  The results highlight the 
differences with the BCLC algorithm. 
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PATIENTS AND METHODS 
For this study, we combined HCC cohorts that were assessed in three 
different European centres: the cohort from Clinica Universidad de Navarra, 
Spain; the cohort from Newcastle Hospitals, UK; and the cohort from 
University Hospital Bern, Switzerland with a total of 1693 patients.  The 
diagnosis of HCC was established following the EASL clinical practice 
guidelines.[1] All patients older than 18 years were invited to participate and 
standardised prospective information was collected. In Pamplona, patient 
information was collected in line with local hospitals and ethics committee 
(Comité Ético de Investigación, Clínica Universitaria de Navarra, Pamplona, 
Spain) guidelines and approval. In Newcastle, patient information was 
collected as part of an audit approved by the Newcastle upon Tyne Hospitals 
NHS Fundation Trust and shared in an anonymised form. In Bern, patient 
information collection was approved by local ethics committee (Kantonale 
Ethikkommission Bern, Bern, Switzerland). All enrolled patients signed an 
informed consent. The following variables were documented: tumour status 
(size, number of nodules), presence of vascular invasion, existence of 
metastases, BCLC classification, Child-Pugh grade and its variables (albumin, 
bilirubin, prothrombin time, ascites and encephalopathy), Eastern Cooperative 
Oncology Group performance status (ECOG PS), comorbidity, etiology and 
treatment. The HKLC classification was applied to each patient using ECOG 
PS, Child-Pugh grade, presence or absence of extrahepatic metastasis, and 
tumour status.  The latter was defined by the size of the tumour, the number 
of nodules, and the presence or absence of intrahepatic vascular invasion. 
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OS was defined as the time from the date of first diagnosis of HCC to the time 
of death, last follow-up evaluation or the date of data censoring.  Cumulative 
survival rates were calculated by the Kaplan–Meier method, and survival 
curves were compared using the log-rank test. Cox proportional hazards 
regression, with each staging system as a covariate, was used to estimate 
Nagelkerke pseudo R2 to determine the percentage variance of the predicted 
OS (i.e. to assess prediction accuracy) by each model.[17] In order to 
compare the models, we calculated the Bayesian Information Criterion (BIC) 
for each model and calculated the differences between the two BIC.[18]. The 
Harrell’s concordance index was also calculated for each model[19]. In order 
to compare the characteristics of the three cohorts and the hypothetical 
number of patients undergoing either curative or palliative therapy according 
both treatment algorithms, we used the Pearson chi-square test.  All analyses 
were conducted using R version 3.1.1 [20], and a p value of less than 0.05 
was considered statistically significant.  
 
RESULTS 
A total of 1575 eligible adult HCC patients were included (Spanish cohort, 
n=738; UK cohort, n=631 and Swiss cohort n=206). The clinical and tumour 
burden characteristics of these patients are shown in Table 1. The median 
(range) age at presentation was 65 (18–92) years, and the majority (82.5%) of 
patients were male.  Etiology of HCC was ASH for 483 patients (30.7%), HCV 
for 450 patients (28.6%), NASH for 209 patients (13.3%), HBV for 161 
patients (10.2%) and hemochromatosis for 63 patients (4.0%). Seventy-five 
percent of the patients had a cirrhotic liver, among them, 58% of the cirrhotic 
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patients were Child-Pugh A, 29.5% Child-Pugh B and 12.5% Child-Pugh C. 
Forty-five percent of patients had a solitary lesion, 27.1% had 2–3 lesions and 
29.9% >3 lesions.  The size of the biggest nodule was ≤2 cm in 12.4% of 
patients, >2 to ≤5 cm in 43.8% and >5 cm in 43.8%. Treatment details 
according to BCLC and HKLC stages are detailed in Supplementary Tables 1 
and 2 and the median overall survival according to BCLC stages and 
treatment options are detailed in Supplementary Table 3.  
 
Performance as a staging system 
When applied to our patients, the 9-stages HKLC staging system estimated 
Kaplan–Meier OS curves were not clearly distinct from each other (Figure 1), 
although an overall Log-Rank p < 0.001.  Pairwise Log-rank tests between 
stages provided the following results (Supplementary Table 4): stage I 
(differing in ECOG PS 0 vs 1 or Child-Pugh A vs B) was not significantly 
different (p=0.212) from stage IIa; stage IIIa (differing in Child-Pugh B vs A 
and tumor status) was not significantly different (p=0.085) from stage IVa; 
stage IIIa (differing in ECOG PS 0-1 vs 2-4 or Child-Pugh B vs C or tumor 
status) was not significantly different (p=0.567) from stage Va; stage IIIb 
(differing in tumor status and presence of metastasis) was not significantly 
different (p=0.906) from stage IVa; stage IIIb (differing in ECOG PS 0-1 vs 2-4 
or Child-Pugh A/B vs C or tumor status) was not significantly different 
(p=0.129) from stage Va; stage IVa (differing in Child-Pugh A vs B) was not 
significantly different (p=0.053) from stage IVb; stage IVa (differing in ECOG 
PS 0-1 vs 2-4 or Child-Pugh A vs C or tumor status) was not significantly 
different (p=0.241) from stage Va. Stage Va particularly lacks of distinction 
from other HKC substages. This stage concerns patients with advanced tumor 
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who were largely transplanted (24.2%) and therefore expected to have a good 
survival. Excluding these patients improves a little bit the stage distinction but 
not completely (remains statistically indistinct from stages IVa and IVb). 
HKLC with only five stages demonstrated a better separation of the survival 
curves (Figure 2).  Although some curves are not clearly separated anymore 
after 7 years, the overall log-rank test confirmed the significant survival 
differences between stages (p < 0.001). The BCLC classification (A, B, C, D) 
also provided a good overall stratification (Figure 3), whereby the log-rank test 
between all stages was highly significant (p < 0.001).  In order to compare the 
two models (BCLC A, B, C, D versus HKLC I, II, III, IV, V), we performed Cox 
proportional hazards regression with each staging system as a covariate 
(Loglikelihood for BCLC -6903.9, for HKLC -6941.5). Based on these results, 
we estimated the Nagelkerke pseudo R2 which was 0.354 for BCLC and 
0.308 for HKLC. The BIC was 13814.77 for BCLC and 13889.98 for HKLC. 
The difference between the two BIC was 75.21, which gives strong evidence 
that the BCLC is a better model to predict the survival than the HKLC 
system[18]. Finally, we calculated Harrell’s C-index with 0.739 for BCLC and 
0.728 for HKLC. This result also gives an indication that the BCLC 
classification provides a better fit of the survival than the HKLC system.  
If the patients of our cohort were mainly treated following the BCLC treatment 
algorithm, it could lead in a potential bias of this result. Therefore, we 
assessed the number of patients that were treated accordingly to their 
respective stage for both treatment algorithms. 537 (34.1%) patients were 
treated according the BCLC treatment algorithm and 603 (38.3%) patients 
were treated according to the HKLC treatment algorithm (see Supplementary 
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Tables 2 & 3 for further details). Therefore, treatments received by the 
patients of the cohort cannot be considered as a potential bias that would give 
an advantage to the BCLC staging system. In order to definitively avoid any 
bias due to given treatments we also tested the two staging systems on 
patients who only got best supportive care. Based on Cox proportional 
hazards regression we obtained for BCLC a Likelihood of -2380.3 and -2386.6 
for HKLC. Based on this, Nagelkerke pseudo R2 was 0.367 for BCLC and 
0.349 for HKLC. BIC was 4766.71 for BCLC and 4779.34 for HKLC, 
difference was 12.63, which again gives strong evidence that the BCLC is a 
better model to predict the survival than the HKLC system. Finally, Harrell’s C 
index was 0.699 for BCLC and 0.692 for HKLC, which once more speaks for 
the BCLC model. 
 
Performance as a treatment algorithm 
Both classification systems suggest one or more treatment for each stage. 
Based on our cohort, we looked at the number of patients who would benefit 
from a curative therapy if the suggested treatment allocation of each 
classification system was strictly applied. If the HKLC treatment algorithm 
would be strictly applied, almost one third of the whole cohort (exactly 500 
more patients) would be treated with a curative therapy instead of being 
tagged to a palliative therapy when following the BCLC treatment (p < 0.001). 
Curative therapies are usually associated with a better overall survival than 
palliative therapy. Therefore, this result suggests that following the HKLC 
treatment algorithm instead of the BCLC may lead in an increased overall 
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survival for patient with HCC. However, this assumption needs to be 
assessed. 
 
DISCUSSION 
By applying the HKLC classification system to a large set of European 
patients combining three cohorts from centres in three different countries, we 
found that the Kaplan–Meier curves of the nine different substages did not 
satisfactorily distinguish survival, although this was markedly improved when 
using five stages. Despite highly significant survival differences between the 
HKLC five stages, the overall performance of the BCLC staging system was 
better for predicting survival. However, using the HKLC treatment algorithm 
would offer curative treatments to a larger number of patients than the BCLC 
does.  
We pooled three cohorts from centres in three different countries. Public 
health systems differ in these, and therefore clinical characteristics were 
different over the three cohorts. This allowed us to build a pooled cohort 
representative of the European diversity and has a good repartition of the 
collective of patients among the different categories (e.g. early and advanced 
stages) which is mandatory to assess a staging system which covers all 
stages of the disease. The ideal staging system would be one that accurately 
predicts the survival for all patients, as well as to support the selection of the 
treatment offering the best survival opportunity across all stages of disease.  
The HKLC staging system classifies patients in five stages and nine 
substages. Some substages display similar survival curves and could be 
merged without loss of information in our European cohort. The simplified 
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HKLC system classified patients in five stages with different survivals and 
could be used to predict prognosis.  However, the five-stage HKLC staging 
system was not more accurate than the BCLC staging system.  The 5-stage 
HKLC staging system explains 30.8% of the variance, which measures the 
ability of a staging system to predict accurately OS, whereas the BCLC 
staging, explains 35.4% of the variance. This result indicates that in Europe, 
where the HCC etiologies are more diverse than in Asia, the HKLC staging 
system does not perform better than the BCLC system as a prognostic tool. 
This finding is confirmed by the Bayesian Information Criterion (BIC) – and the 
difference between these – and the Harrell’s C index. We showed that this 
result was not biased by the treatment received by the patients, and that the 
result was the same if only patients who received best supportive care were 
taken into account. Adhoute et al. used a French cohort of 665 patients to 
compare the HKLC and the BCLC staging systems[21]. They found no 
difference between the two staging system in the ability to predict the OS. Our 
pooled cohort from three different countries probably represents better the 
European heterogeneity of diagnosed HCC and is therefore more suitable to 
assess the HKLC staging system in Europe.   
The HKLC provides a treatment algorithm, as does the BCLC classification 
system. In our European cohort, if the HKLC treatment algorithm was strictly 
applied, almost one third of our cohort (n=500), who would be tagged to a 
palliative therapy following the BCLC algorithm, would be tagged to a curative 
one. To really benefit the patients, this curative treatment indication for more 
advanced tumour should be linked with a better overall survival. Therefore, 
there is a need to assess those differences in treatment allocation. For this 
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purpose, one provocative finding made by Yau et al. was that patients with 
intermediate stage HCC had a better survival if treated with surgery rather 
than TACE [16].  The EASL-EORTC and AASLD guidelines, which adopted 
the BCLC staging system, recommend resection for single asymptomatic 
HCC in patients with preserved liver function and normal portal pressure and 
bilirubin, and TACE for patients in BCLC B stage [1], [22]. TACE is a palliative 
approach with the goal of controlling tumour growth locally, where surgical 
resection is a curative approach with the goal of eradicating HCC. Better OS 
for patients with intermediate HCC undergoing surgical resection has already 
been published [23], [24]. It was also reported that hepatic resection can be 
performed in patients with major vascular invasion [25] and in patients with 
large or multinodular HCC [26].  Some authors suggest that surgical resection 
benefits BCLC B patients, but should be performed under strict intraoperative 
ultrasound guidance [27]. Taken together, these results imply that a 
subpopulation of patients with intermediate HCC do better with surgical 
resection than with TACE, as suggested by the HKLC treatment algorithm.  
The HKLC staging system shows a more aggressive treatment algorithm than 
the BCLC staging system. This could probably be explained by HBV being the 
main etiology of HCC in Asia. As a matter of fact, it has been shown that 
cirrhotic patients with an early HBV-associated HCC are good candidates for 
surgical resection and have the same OS than non-cirrhotic patients[28].   
In interpreting the results of our study, a number of limitations should be taken 
into consideration. The data were prospectively collected, but retrospectively 
analyzed, which can lead to several biases.  
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In conclusion, the BCLC staging system offers a more accurate survival 
prediction than the HKLC staging system in Europe, where the etiologies for 
HCC are more diverse than in Asia. Although the HKLC staging system offers 
suboptimal performances for the survival prediction in our European cohort, 
following its treatment algorithm offers curative therapy to a larger number of 
HCC patients than the BCLC algorithm does.  
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TABLES 
 
 Pamplona Newcastle Bern Total P Value 
 N % N % N % N %  
Sex         .042 
Male 609 82.5 509 80.7 182 88.3 1300 82.5  
Female 129 17.5 122 19.3 24 11.7 275 17.5  
BCLC         .000 
A 181 24.5 89 14.1 88 42.7 358 22.7  
B 276 37.4 95 15.1 71 34.5 442 28.1  
C 214 29.0 284 45.0 36 17.5 534 33.9  
D 67 9.1 163 25.8 11 5.3 241 15.3  
HKLC         .000 
I 165 22.4 103 16.3 32 15.5 300 19.0  
II 207 28.0 145 23.0 110 53.4 462 29.3  
III 209 28.3 76 12.0 24 11.7 309 19.6  
IV 61 8.3 39 6.2 5 2.4 105 6.7  
V 96 13.0 268 42.5 35 17.0 397 25.3  
Etiology          
ASH 215 29.1 178 28.2 90 43.7 483 30.7 .000 
HBV 90 12.2 29 4.6 42 20.4 161 10.2 .000 
HCV 323 43.8 65 10.3 62 30.1 450 28.6 .000 
NASH 4 0.5 136 21.6 69 33.5 209 13.3 .000 
Hemochromatosis 16 2.2 34 5.4 13 6.3 63 4.0 .000 
Cirrhosis 565 76.6 456 72.3 167 81.1 1188 75.4 .024 
Child Pugh1         .000 
A 333 59.0 240 52.9 114 68.3 687 58.0  
B 177 31.4 126 27.8 47 28.1 350 29.5  
C 54 9.6 88 19.4 6 3.6 148 12.5  
Tumor size         .000 
≤2 
 
70 10.2 70 11.1 49 24.1 189 12.4  
>2 to ≤5 
 
319 46.6 265 42.0 81 39.9 665 43.8  
>5 
 
296 43.2 296 46.9 73 36.0 665 43.8  
No. of nodules         .000 
Single 267 39.5 329 52.1 83 40.7 679 44.9  
Oligonodular (2-3) 201 29.7 139 22.0 70 34.3 410 27.1  
Multinodular (>3) 208 30.8 163 25.8 51 25.0 422 27.9  
Table 1: Clinical and tumour burden information for patients in the 3 cohorts.  
BCLC: Barcelona Clinic Liver Cancer, HKLC: Hong-Kong Liver Cancer, ASH: Alcoholic 
steatohepatitis, HBV: Hepatitis B virus, HCV: Hepatitis C virus, NASH: non-alcoholic 
steatohepatitis. 
1Child-Pugh is given for cirrhotic patients only. 
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FIGURE LEGENDS 
 
Figure 1: Kaplan–Meier estimated overall survival curves of the Hong Kong Liver Cancer 
(HKLC) staging system (nine stages) 
 
Figure 2: Kaplan–Meier estimated overall survival curves of the Hong Kong Liver Cancer 
(HKLC) staging system (five stages) 
 
Figure 3: Kaplan–Meier estimated overall survival curves of the Barcelona Clinic Liver 
Cancer (BCLC) staging system (four stages). 
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